trb_welcome.jpg

 

The mission of TRB Chemedica Group is to develop innovative and patented pharmaceutical products and medical devices in niche therapeutic areas: rheumatology, ophthalmology and neurology.


Video on Dry Eyeeye_pic.jpg

In recent years the nosology of Dry Eye has greatly changed. Professor Baudouin, MD, PhD from National Ophthalmologiy Hospital XV-XX, Vision Institute of Paris explains through this didactic video the complexity of the Dry Eye disease. Moving beyond the simple name of Dry Eye syndrome, we now consider the condition to be Dry Eye disease, insisting on the lack of tears, the lacrimal inflammation and hyperevaporation leading to self-sustaining loops of neurogenic and palpebral inflammations.

View the video


Ostenil-tendon_petit.jpg

An Innovative Approach in the Treatment of Painful Tendinopathy

OSTENIL® TENDON was developed to treat pain and restricted mobility in tendon disorders. It is a conservative treatment based on the biomechanical properties of hyaluronic acid.

OSTENIL® TENDON is injected into the tendon sheath (intrasheath injection) or around the affected tendon (peritendinous injection) once a week for a total of 2 injections.

OSTENIL® TENDON provides rapid symptom relief in painful tendinopathy

Pack_Ostenil_Tendon petit.jpgpdf OSTENIL® Tendon instructions for use
Distributors
trb_contact.gif Contacts

News-Events
 
 
  • English